Novità in area Onco-Ema su Tecentrig, Rybrevant, Libtayo e Enhertu

Tecentriq (atezolizumab)

EMA reminds physicians to use Tecentriq (atezolizumab) with nab-paclitaxel for treating breast cancer
EMA confirmed its previous recommendation to use Tecentriq only in combination with nab-paclitaxel and not with conventional paclitaxel when treating patients with locally advanced or metastatic triple-negative breast cancer that cannot be surgically removed. Tecentriq is a medicine for treating the following cancers: urothelial cancer, lung cancer and triple-negative breast cancer.

Rybrevant (amivantamab-vmjw)

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
The first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Rybrevant.

Libtayo (cemiplimab)

Regeneron – extension indication Non-Small Cell Lung Cancer
CHMP positive opinion for extension indication of Libtayo as monotherapy first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.

Enhertu (trastuzumab deruxtecan)

Daiichi Sankyo HER2 target breast cancer treatment
Aggiornamento RCP per estensione della validità del farmaco a 3 anni